Trial Profile
A Phase 1, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Efficacy of NBM-BMX in Subjects With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Apr 2022
Price :
$35
*
At a glance
- Drugs NBM BMX (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors NatureWise Biotech & Medicals Corporation
- 11 Apr 2022 Status changed from recruiting to completed.
- 30 Aug 2021 Planned End Date changed from 1 Jul 2021 to 1 Jul 2022.
- 30 Aug 2021 Planned primary completion date changed from 1 Jul 2021 to 1 Dec 2021.